Malte Erich Kornhuber

Malte Erich Kornhuber


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Clinical Imaging
Verified
Journal Article
Closed access
HMHans-Jonas Meyer
Hans-Jonas Meyer
EFEckhard Fiedler
Eckhard Fiedler
MKMalte Erich Kornhuber
Malte Erich Kornhuber
RSRolf Peter Spielmann
Rolf Peter Spielmann
ASAlexey Surov
Alexey Surov

2 September 2006 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
MKMalte Erich Kornhuber
Malte Erich Kornhuber
SMS. Markau
S. Markau
ASAlexey Surov
Alexey Surov
JHJ. Herde
J. Herde
TLT. Langer
T. Langer

5 June 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
APAndreas Posa
Andreas Posa
INIzabela Niśkiewicz
Izabela Niśkiewicz
AEAlexander Emmer
Alexander Emmer
FHFrank Hanisch
Frank Hanisch
MKMalte Erich Kornhuber
Malte Erich Kornhuber
Complex repetitive discharges (CRDs) are poorly understood phenomena in needle electromyography (EMG) recordings. The data presented here suggest that CRDs may mainly be a sign of motor unit reinnervation. EMG “video” data of 108 CRDs from neurogenic (ND, n = 39) and myogenic (MD, n = 14) disorders were retrospectively analyzed for cycle duration, potential-free time intervals, spike components (SC), maximum amplitudes, blockade, and increased jitter. CRD-SC in ND disorders (9.3 ± 7.8) outnumbered those in MD disorders (6.3 ± 6.2). The CRD cycle duration was correlated with SC and silent periods (p each < 0.000001). Blockade was observed in 36% and increased jitter in 27% of the CRDs. A higher number of CRD-SC in ND vs. MD fits the known differences in motor unit dimensions. Blockade and increased jitter are known features of diseased neuromuscular junctions, such as during reinnervation. The SC patterns of single CRD cycles resemble reinnervation potentials. Thus, CRDs may result from myo-axonal re-excitation in sprouting motor units. The purpose of this investigation was to better understand the circumstances under which CRDs may occur and eventually to contribute to the understanding of their pathogenesis.

12 February 2017 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
PDF file
APAndreas Posa
Andreas Posa
AEAlexander Emmer
Alexander Emmer
MKMalte Erich Kornhuber
Malte Erich Kornhuber

1 July 2016 in Clinical Neurophysiology
Verified
Journal Article
Closed access
IZI. Zakharova
I. Zakharova
JKJ.C. Kohlmeyer
J.C. Kohlmeyer
MKMalte Erich Kornhuber
Malte Erich Kornhuber

15 November 2004 in Fortschritte der Neurologie · Psychiatrie
Verified
Journal Article
Closed access
MKMalte Erich Kornhuber
Malte Erich Kornhuber
PPP. Presek
P. Presek
SZS. Zierz
S. Zierz
Die Wirksamkeit verschiedener Substanzen auf Schubparameter ist bei Patienten mit schubhaft remittierender Multipler Sklerose (MS) gut belegt. Patienten mit progredienten MS-Verläufen profitieren dagegen von Immuntherapie kaum. Gegenwärtig wird daher der Behandlungsbeginn nach dem ersten Schub propagiert, auch mit dem Ziel, Degeneration und Behinderung entgegenzuwirken. In der vorliegenden Übersicht wird diese Vorstellung einer kritischen Prüfung unterzogen. Tatsächlich gibt es keine Evidenz, dass durch frühen Beginn einer Immuntherapie die sekundäre Progression verzögert oder abgeschwächt werden kann. Ausgedehnte Degeneration lässt sich früh im Krankheitsverlauf und unabhängig von Entzündungsaktivität fassen. Autoimmunität per se stellt offensichtlich kein ausreichendes pathogenetisches Konzept für MS dar. Alternativ wird ein Virus-Superantigen-Dualismus als Ursache der unterschiedlichen Pathomechanismen der MS vorgestellt. Zusammenfassend ist eine Evidenz-basierte Immuntherapie an der tatsächlichen Entzündungsaktivität der Erkrankung auszurichten. Geeignet ist dafür insbesondere der Abstand zwischen zwei Schüben. It is well established that relapses can be suppressed by different substances in patients with relapsing-remitting multiple sclerosis (MS). In contrast, patients with progressive forms of MS do hardly respond to immune therapy. Therefore, start of immune therapy after the first relapse has been proposed, especially in order to prevent degeneration and disability. This view is challenged in the present review. Actually no evidence exists in support of a retardation or an attenuation of secondary progression by early immune therapy. Widespread degeneration occurs early and progresses independently from inflammatory plaques. Therefore, autoimmunity per se is no adequate paradigm to explain MS-pathogenesis entirely. A virus/superantigen-dualism is proposed to explain the different parts of MS, instead. It is concluded that evidence-based immune therapy should be adapted to the actual inflammatory activity of the disease. A suitable parameter for this purpose is the interval between 2 relapses.